March 14, 2017
Johnson & Johnson announced that final Phase 1 clinical trial data published in JAMA: The Journal of the American Medical Association show that the investigational “prime-boost” Ebola vaccine regimen of Janssen Pharmaceutical Companies induced a durable immune response in 100 percent of healthy volunteers one year following vaccination.
The Oxford Vaccine Group at the University of Oxford led the Phase 1 study. It tested the prime-boost Ebola vaccine regimen being developed by Janssen Vaccines & Prevention B.V. that is based on AdVac® technology from Janssen and MVA-BN® technology from Bavarian Nordic A/S. Healthy volunteers were given one vaccine dose to prime their immune system, and the alternative vaccine to boost their immune response. In order to confirm these findings, additional Phase 1, 2 and 3 studies are ongoing.
Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson, said: “The world needs a vaccine to help prevent or mitigate future Ebola outbreaks, and ideally it should provide sustained protection for at-risk populations. We are committed to helping the global community finish the job of finding an Ebola preventive vaccine. Together with our EBOVAC1 consortium partners the London School of Hygiene & Tropical Medicine, University of Oxford, and Inserm, we are grateful for the ongoing support of Europe’s Innovative Medicines Initiative (IMI), BARDA and NIH. Additionally, we will work with new mechanisms like the Coalition for Epidemic Preparedness Innovations (CEPI), as well as regulators and other key stakeholders, to forge a path forward to protect global health.”
Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination in Phase 1 Study, Reported by Johnson & Johnsonlast edit: 2017-03-25T15:30:56+00:00da